Non-Muscle Invasive Bladder Carcinoma — Trials

Non-Muscle Invasive Bladder Carcinoma — Trials · CancerIndex

Clinical trials

Registered studies

100 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 55
Recruiting: 35
Ph III recruiting: 8
Growth YoY: —
Industry share: 36%
Top sponsor: Janssen Research & Development, LLC
Termination share: —

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (7)

clinicaltrialsPublishedShowing 1–15 of 15 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT06919965	A Study to Evaluate TAR-210 Versus Intravesical Chemotherapy Treatment in Participants With High Risk Non-Muscle-Invasive Bladder Cancer(MoonRISe-3)	recruiting	Phase 3	220	Janssen Research & Development, LLCINDUSTRY	15	Sep 28, 2026	clinicaltrials
NCT06211764	A Study of TAR-200 Versus Intravesical Chemotherapy in Participants With Recurrent High-Risk Non-Muscle-Invasive Bladder Cancer (HR-NMIBC) After Bacillus Calmette-Guérin (BCG)(SunRISe-5)	active not recruiting	Phase 3	272	Janssen Research & Development, LLC